COMPOUNDS / SARM / MK-2866
SARM
MK-2866
MEDIUM RISK
Performance & Enhancement / SARM / Recomposition
BEST FOR:Recomposition●●●●●●●○○○7/10
MK-2866 · OSTARINE · ENOBOSARM · GTX-024 · S-22 · OSTARINE
SARMAndrogen ReceptorBodybuildingCachexiaWADA BannedResearch Chemical
Selective androgen receptor modulator developed for muscle-wasting conditions; widely used off-label for body recomposition.
— QUICK REFERENCE
ROUTE / DOSAGE
LOW10mg
STANDARD20-25mg
HIGH50mg
Note: Once daily; cycles typically 8-12 weeks followed by PCT
CYCLE
8-12 weeks on
followed by 4-week PCT
do not exceed 12 weeks without bloodwork
BIOAVAILABILITY
~40-50% oral
ACTIVE DURATION
~24 hours (subjective)
STORAGE
Room temperature
dry
away from light
keep in original container
DURATION BREAKDOWN
Total24 hours
Onset1-2 weeks
Come up1-2 weeks
Peak2-4 hours
Offsetgradual over 24 hours
After effects2-4 weeks
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Increased lean muscle mass
Improved muscle strength
Enhanced bone density
Accelerated recovery
Mild fat loss
Increased vascularity
§ 02 — RISKS
Dose-dependent cardiotoxicity including fibrosis and cardiomyopathy markers
Elevated hepatic transaminases
Hypercalcaemia
Testosterone suppression with extended use
WADA-prohibited substance causing positive doping tests
No regulatory approval for human use
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE
Enobosarm completed Phase III clinical trials for cancer cachexia, demonstrating significant increases in lean body mass but inconsistent improvements in physical function. A 2024 Phase 2 trial in ER-positive, HER2-negative breast cancer showed anti-tumour activity via androgen receptor activation. Preclinical data from 2023 revealed cardiotoxic effects including increased fibrosis markers and cardiomyopathy markers, with greater severity in males. No SARM has received full regulatory approval for any indication. Evidence for performance enhancement in healthy adults is limited to anecdotal reports and animal studies.
§ 06 — SOURCES
[4]
Activity and safety of enobosarm in advanced breast cancer (Study G200802)
pubmed.ncbi.nlm.nih.gov ↗[5]
SARMs - potential anabolic drugs for the treatment of cachexia and frailty syndrome
pubmed.ncbi.nlm.nih.gov ↗Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT